---
document_datetime: 2025-12-02 06:06:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-sun.html
document_name: bortezomib-sun.html
version: success
processing_time: 0.1459479
conversion_datetime: 2025-12-27 13:22:28.977476
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Bortezomib Sun

[RSS](/en/individual-human-medicine.xml/65437)

##### Authorised

This medicine is authorised for use in the European Union

bortezomib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Bortezomib Sun](#news-on)
- [More information on Bortezomib Sun](#more-information-on-bortezomib-sun-970)
- [Related information](#related-information-438)
- [Product information - with tracked changes](#product-information-with-tracked-changes-80177)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Bortezomib Sun. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Bortezomib Sun.

For practical information about using Bortezomib Sun, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Bortezomib Sun and what is it used for?

Bortezomib Sun is a cancer medicine used to treat multiple myeloma, a blood cancer, in the following groups of patients:

- adults whose disease is getting worse after at least one other treatment and who have already had, or cannot undergo, blood stem-cell transplantation. Bortezomib Sun is either used on its own in these patients or in combination with pegylated liposomal doxorubicin or dexamethasone;
- previously untreated adults who cannot have high-dose chemotherapy with blood stem-cell transplantation. In these patients, Bortezomib Sun is used in combination with melphalan and prednisone;
- previously untreated adults who are going to receive high-dose chemotherapy followed by blood stem-cell transplantation. In this group of patients, Bortezomib Sun is used in combination with dexamethasone, or with dexamethasone plus thalidomide.

Bortezomib Sun is also used to treat mantle cell lymphoma, another blood cancer, in untreated adults who cannot have blood stem-cell transplantation. For mantle cell lymphoma, Bortezomib Sun is used in combination with rituximab, cyclophosphamide, doxorubicin and prednisone.

Bortezomib Sun is a 'generic medicine'. This means that Bortezomib Sun is similar to a 'reference medicine' already authorised in the European Union (EU) called Velcade.

Bortezomib Sun contains the active substance bortezomib.

## How is Bortezomib Sun used?

The medicine can only be obtained with a prescription and treatment should only be started and given under the supervision of a doctor who has experience in the use of cancer chemotherapy.

Bortezomib Sun is available in vials as a 3.5 mg powder to be made up into a solution for injection into a vein or under the skin. Bortezomib Sun must not be given by other routes.

The recommended dose is calculated using the patient's height and weight). When given into a vein, the solution is injected through a catheter (a thin sterile tube). At least 72 hours must pass between two doses of Bortezomib Sun. When injected under the skin, it is given in the thigh or abdomen (tummy).

Doses of Bortezomib Sun are given with rest periods between doses, in treatment cycles of three to six weeks depending on whether Bortezomib Sun is given alone or in combination with other medicines. If a patient develops severe side effects, treatment must be discontinued, delayed or the dose adjusted.

Patients with moderate or severe liver problems should be treated with lower doses. For more information on the use of Bortezomib Sun see the summary of product characteristics (also part of the EPAR).

## How does Bortezomib Sun work?

The active substance in Bortezomib Sun, bortezomib, is a proteasome inhibitor. It blocks proteasome, which is a system in cells that breaks down proteins that are no longer needed. Blocking the proteasome system causes the cell to die. Cancer cells are more sensitive than normal cells to the effects of proteasome inhibitors like bortezomib.

## How has Bortezomib Sun been studied?

The company provided data from the published literature on bortezomib. No additional studies were needed as Bortezomib Sun is a generic medicine that is given by injection and contains the same active substance as the reference medicine, Velcade.

## What are the benefits and risks of Bortezomib Sun?

Because Bortezomib Sun is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Bortezomib Sun approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Bortezomib Sun has been shown to be comparable to Velcade. Therefore, the CHMP's view was that, as for Velcade, the benefit outweighs the identified risk. The Committee recommended that Bortezomib Sun be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Bortezomib Sun?

The company that markets Bortezomib Sun will supply educational material to healthcare professionals on making up and giving the injection, calculating the dose, and prescribing and giving the correct treatment for patients receiving blood stem-cell transplantation.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bortezomib Sun have also been included in the summary of product characteristics and the package leaflet.

## Other information about Bortezomib Sun

The European Commission granted a marketing authorisation valid throughout the European Union for Bortezomib Sun on 22 July 2016.

For more information about treatment with Bortezomib Sun, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Bortezomib Sun : EPAR - Summary for the public

Reference Number: EMA/CHMP/379917/2016

English (EN) (98.88 KB - PDF)

**First published:** 04/08/2016

**Last updated:** 04/08/2016

[View](/en/documents/overview/bortezomib-sun-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-732)

български (BG) (125.2 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/bg/documents/overview/bortezomib-sun-epar-summary-public_bg.pdf)

español (ES) (99.06 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/es/documents/overview/bortezomib-sun-epar-summary-public_es.pdf)

čeština (CS) (123.61 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/cs/documents/overview/bortezomib-sun-epar-summary-public_cs.pdf)

dansk (DA) (98.01 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/da/documents/overview/bortezomib-sun-epar-summary-public_da.pdf)

Deutsch (DE) (99.63 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/de/documents/overview/bortezomib-sun-epar-summary-public_de.pdf)

eesti keel (ET) (97.32 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/et/documents/overview/bortezomib-sun-epar-summary-public_et.pdf)

ελληνικά (EL) (127.68 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/el/documents/overview/bortezomib-sun-epar-summary-public_el.pdf)

français (FR) (99.37 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/fr/documents/overview/bortezomib-sun-epar-summary-public_fr.pdf)

hrvatski (HR) (116.72 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/hr/documents/overview/bortezomib-sun-epar-summary-public_hr.pdf)

italiano (IT) (97.7 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/it/documents/overview/bortezomib-sun-epar-summary-public_it.pdf)

latviešu valoda (LV) (119.09 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/lv/documents/overview/bortezomib-sun-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (120.15 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/lt/documents/overview/bortezomib-sun-epar-summary-public_lt.pdf)

magyar (HU) (118.51 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/hu/documents/overview/bortezomib-sun-epar-summary-public_hu.pdf)

Malti (MT) (123.6 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/mt/documents/overview/bortezomib-sun-epar-summary-public_mt.pdf)

Nederlands (NL) (98.4 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/nl/documents/overview/bortezomib-sun-epar-summary-public_nl.pdf)

polski (PL) (116.87 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/pl/documents/overview/bortezomib-sun-epar-summary-public_pl.pdf)

português (PT) (99.05 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/pt/documents/overview/bortezomib-sun-epar-summary-public_pt.pdf)

română (RO) (119.71 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/ro/documents/overview/bortezomib-sun-epar-summary-public_ro.pdf)

slovenčina (SK) (122.77 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/sk/documents/overview/bortezomib-sun-epar-summary-public_sk.pdf)

slovenščina (SL) (115.92 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/sl/documents/overview/bortezomib-sun-epar-summary-public_sl.pdf)

Suomi (FI) (97.61 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/fi/documents/overview/bortezomib-sun-epar-summary-public_fi.pdf)

svenska (SV) (98.21 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/sv/documents/overview/bortezomib-sun-epar-summary-public_sv.pdf)

## Product information

Bortezomib Sun : EPAR - Product Information

English (EN) (847.34 KB - PDF)

**First published:** 04/08/2016

**Last updated:** 14/10/2025

[View](/en/documents/product-information/bortezomib-sun-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-568)

български (BG) (940.48 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/bg/documents/product-information/bortezomib-sun-epar-product-information_bg.pdf)

español (ES) (805.51 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/es/documents/product-information/bortezomib-sun-epar-product-information_es.pdf)

čeština (CS) (916.89 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/cs/documents/product-information/bortezomib-sun-epar-product-information_cs.pdf)

dansk (DA) (764.41 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/da/documents/product-information/bortezomib-sun-epar-product-information_da.pdf)

Deutsch (DE) (863.86 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/de/documents/product-information/bortezomib-sun-epar-product-information_de.pdf)

eesti keel (ET) (742.12 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/et/documents/product-information/bortezomib-sun-epar-product-information_et.pdf)

ελληνικά (EL) (996.42 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/el/documents/product-information/bortezomib-sun-epar-product-information_el.pdf)

français (FR) (837.73 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/fr/documents/product-information/bortezomib-sun-epar-product-information_fr.pdf)

hrvatski (HR) (845.26 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/hr/documents/product-information/bortezomib-sun-epar-product-information_hr.pdf)

íslenska (IS) (810 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/is/documents/product-information/bortezomib-sun-epar-product-information_is.pdf)

italiano (IT) (849.73 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/it/documents/product-information/bortezomib-sun-epar-product-information_it.pdf)

latviešu valoda (LV) (948.17 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/lv/documents/product-information/bortezomib-sun-epar-product-information_lv.pdf)

lietuvių kalba (LT) (926.24 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/lt/documents/product-information/bortezomib-sun-epar-product-information_lt.pdf)

magyar (HU) (912.25 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/hu/documents/product-information/bortezomib-sun-epar-product-information_hu.pdf)

Malti (MT) (945.53 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/mt/documents/product-information/bortezomib-sun-epar-product-information_mt.pdf)

Nederlands (NL) (803.81 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/nl/documents/product-information/bortezomib-sun-epar-product-information_nl.pdf)

norsk (NO) (852.58 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/no/documents/product-information/bortezomib-sun-epar-product-information_no.pdf)

polski (PL) (976.03 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/pl/documents/product-information/bortezomib-sun-epar-product-information_pl.pdf)

português (PT) (922.14 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/pt/documents/product-information/bortezomib-sun-epar-product-information_pt.pdf)

română (RO) (1.04 MB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/ro/documents/product-information/bortezomib-sun-epar-product-information_ro.pdf)

slovenčina (SK) (879.53 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/sk/documents/product-information/bortezomib-sun-epar-product-information_sk.pdf)

slovenščina (SL) (880.47 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/sl/documents/product-information/bortezomib-sun-epar-product-information_sl.pdf)

Suomi (FI) (845.27 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/fi/documents/product-information/bortezomib-sun-epar-product-information_fi.pdf)

svenska (SV) (796.98 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

14/10/2025

[View](/sv/documents/product-information/bortezomib-sun-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000302628 10/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Bortezomib Sun : EPAR - All Authorised presentations

English (EN) (12.29 KB - PDF)

**First published:** 04/08/2016

**Last updated:** 04/08/2016

[View](/en/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-461)

български (BG) (43.09 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/bg/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_bg.pdf)

español (ES) (13.45 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/es/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_es.pdf)

čeština (CS) (41.11 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/cs/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (13.55 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/da/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (13.6 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/de/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (13.47 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/et/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (42.08 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/el/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_el.pdf)

français (FR) (13.38 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/fr/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (45.25 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/hr/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (13.6 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/is/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_is.pdf)

italiano (IT) (13.48 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/it/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (40.99 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/lv/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (40.95 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/lt/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (25.19 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/hu/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (39.76 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/mt/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (13.46 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/nl/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (13.52 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/no/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_no.pdf)

polski (PL) (41.48 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/pl/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_pl.pdf)

português (PT) (13.57 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/pt/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_pt.pdf)

română (RO) (40.66 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/ro/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (41.09 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/sk/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.06 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/sl/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (13.86 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/fi/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (13.56 KB - PDF)

**First published:**

04/08/2016

**Last updated:**

04/08/2016

[View](/sv/documents/all-authorised-presentations/bortezomib-sun-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Bortezomib Sun Active substance bortezomib International non-proprietary name (INN) or common name bortezomib Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutic chemical (ATC) code L01XG01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Bortezomib SUN as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.

Bortezomib SUN in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

Bortezomib SUN in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

Bortezomib SUN in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

## Authorisation details

EMA product number EMEA/H/C/004076

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

SUN Pharmaceutical Industries (Europe) B.V.

Polarisavenue 87

Opinion adopted 26/03/2016 Marketing authorisation issued 22/07/2016 Revision 15

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Bortezomib Sun : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (131.17 KB - PDF)

**First published:** 06/05/2025

**Last updated:** 14/10/2025

[View](/en/documents/procedural-steps-after/bortezomib-sun-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Bortezomib Sun : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (121.72 KB - PDF)

**First published:** 12/01/2017

**Last updated:** 06/05/2025

[View](/en/documents/procedural-steps-after/bortezomib-sun-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Bortezomib Sun-H-C-PSUSA-00000424-202004: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/122201/2021

English (EN) (129.71 KB - PDF)

**First published:** 01/03/2021

[View](/en/documents/scientific-conclusion/bortezomib-sun-h-c-psusa-00000424-202004-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Bortezomib Sun-H-C-PSUSA-00000424-201804 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/169116/2019

English (EN) (66.7 KB - PDF)

**First published:** 20/03/2019

[View](/en/documents/scientific-conclusion/bortezomib-sun-h-c-psusa-00000424-201804-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Bortezomib Sun : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/449636/2016

English (EN) (435.51 KB - PDF)

**First published:** 04/08/2016

**Last updated:** 04/08/2016

[View](/en/documents/assessment-report/bortezomib-sun-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Bortezomib Sun

Adopted

Reference Number: EMA/CHMP/170461/2016

English (EN) (70.43 KB - PDF)

**First published:** 27/05/2016

**Last updated:** 27/05/2016

[View](/en/documents/smop-initial/chmp-summary-opinion-bortezomib-sun_en.pdf)

#### News on Bortezomib Sun

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 May 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-may-2016) 27/05/2016

#### More information on Bortezomib Sun

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC0040760000) (initial marketing authorisation)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Bortezomib Sun : EPAR - Product information - tracked changes

English (EN) (587 KB - DOC)

**First published:** 14/10/2025

[View](/en/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_en.doc)

[Other languages (24)](#file-language-dropdown-564)

български (BG) (720 KB - DOC)

**First published:**

14/10/2025

[View](/bg/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_bg.doc)

español (ES) (574.5 KB - DOC)

**First published:**

14/10/2025

[View](/es/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_es.doc)

čeština (CS) (739 KB - DOC)

**First published:**

14/10/2025

[View](/cs/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_cs.doc)

dansk (DA) (571 KB - DOC)

**First published:**

14/10/2025

[View](/da/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_da.doc)

Deutsch (DE) (177.03 KB - DOCX)

**First published:**

14/10/2025

[View](/de/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (598 KB - DOC)

**First published:**

14/10/2025

[View](/et/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_et.doc)

ελληνικά (EL) (771.5 KB - DOC)

**First published:**

14/10/2025

[View](/el/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_el.doc)

français (FR) (567.5 KB - DOC)

**First published:**

14/10/2025

[View](/fr/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_fr.doc)

hrvatski (HR) (732.5 KB - DOC)

**First published:**

14/10/2025

[View](/hr/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_hr.doc)

íslenska (IS) (571.5 KB - DOC)

**First published:**

14/10/2025

[View](/is/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_is.doc)

italiano (IT) (604.5 KB - DOC)

**First published:**

14/10/2025

[View](/it/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_it.doc)

latviešu valoda (LV) (746.5 KB - DOC)

**First published:**

14/10/2025

[View](/lv/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_lv.doc)

lietuvių kalba (LT) (728 KB - DOC)

**First published:**

14/10/2025

[View](/lt/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_lt.doc)

magyar (HU) (718 KB - DOC)

**First published:**

14/10/2025

[View](/hu/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_hu.doc)

Malti (MT) (735 KB - DOC)

**First published:**

14/10/2025

[View](/mt/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_mt.doc)

Nederlands (NL) (602.5 KB - DOC)

**First published:**

14/10/2025

[View](/nl/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_nl.doc)

norsk (NO) (586.5 KB - DOC)

**First published:**

14/10/2025

[View](/no/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_no.doc)

polski (PL) (757.5 KB - DOC)

**First published:**

14/10/2025

[View](/pl/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_pl.doc)

português (PT) (607 KB - DOC)

**First published:**

14/10/2025

[View](/pt/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_pt.doc)

română (RO) (768 KB - DOC)

**First published:**

14/10/2025

[View](/ro/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_ro.doc)

slovenčina (SK) (707 KB - DOC)

**First published:**

14/10/2025

[View](/sk/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_sk.doc)

slovenščina (SL) (736.5 KB - DOC)

**First published:**

14/10/2025

[View](/sl/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_sl.doc)

Suomi (FI) (591.5 KB - DOC)

**First published:**

14/10/2025

[View](/fi/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_fi.doc)

svenska (SV) (595.5 KB - DOC)

**First published:**

14/10/2025

[View](/sv/documents/product-information-tracked-changes/bortezomib-sun-epar-product-information-tracked-changes_sv.doc)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 14/10/2025

## Share this page

[Back to top](#main-content)